Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Alkem Laboratories Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,903 | 2,968 | 3,440 | 3,324 | 2,936 | 3,032 | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 |
| Expenses + | 2,549 | 2,579 | 2,693 | 2,616 | 2,534 | 2,423 | 2,662 | 2,615 | 2,752 | 2,632 | 3,080 | 2,909 | 3,086 |
| Operating Profit | 353 | 389 | 747 | 708 | 402 | 609 | 753 | 759 | 391 | 739 | 921 | 828 | 517 |
| OPM % | 12% | 13% | 22% | 21% | 14% | 20% | 22% | 23% | 12% | 22% | 23% | 22% | 14% |
| Other Income + | -34 | 66 | 6 | 42 | 76 | 120 | 134 | 93 | 146 | 149 | 104 | 90 | 65 |
| Interest | 29 | 30 | 30 | 25 | 27 | 29 | 28 | 36 | 28 | 30 | 35 | 42 | 54 |
| Depreciation | 78 | 72 | 74 | 70 | 83 | 80 | 79 | 85 | 112 | 88 | 94 | 95 | 106 |
| Profit before tax | 212 | 353 | 648 | 655 | 367 | 619 | 780 | 731 | 396 | 771 | 896 | 781 | 423 |
| Tax % | 68% | 18% | 5% | 8% | 17% | 11% | 10% | 12% | 18% | 13% | 13% | 16% | 40% |
| Net Profit + | 68 | 288 | 615 | 604 | 304 | 550 | 702 | 641 | 322 | 668 | 779 | 653 | 251 |
| EPS in Rs | 5.94 | 23.98 | 51.90 | 49.76 | 24.55 | 45.60 | 57.60 | 52.34 | 25.58 | 55.56 | 63.99 | 53.19 | 19.78 |
Financials of Alkem Laboratories Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,674 | 4,905 | 5,688 | 6,401 | 7,357 | 8,344 | 8,865 | 10,634 | 11,599 | 12,668 | 12,965 | 14,712 |
| Expenses + | 3,248 | 4,038 | 4,687 | 5,392 | 6,237 | 6,868 | 6,920 | 8,580 | 9,977 | 10,419 | 10,452 | 11,707 |
| Operating Profit | 427 | 866 | 1,001 | 1,009 | 1,120 | 1,476 | 1,945 | 2,054 | 1,622 | 2,249 | 2,512 | 3,005 |
| OPM % | 12% | 18% | 18% | 16% | 15% | 18% | 22% | 19% | 14% | 18% | 19% | 20% |
| Other Income + | 176 | 227 | 110 | 115 | 82 | 102 | 230 | 146 | 101 | 186 | 494 | 409 |
| Interest | 81 | 71 | 45 | 55 | 55 | 65 | 59 | 52 | 107 | 112 | 122 | 161 |
| Depreciation | 71 | 93 | 101 | 143 | 193 | 253 | 275 | 304 | 310 | 299 | 357 | 382 |
| Profit before tax | 451 | 928 | 965 | 926 | 955 | 1,260 | 1,842 | 1,844 | 1,305 | 2,023 | 2,527 | 2,871 |
| Tax % | 13% | 19% | 6% | 31% | 19% | 9% | 12% | 9% | 23% | 10% | 12% | 18% |
| Net Profit + | 392 | 752 | 905 | 638 | 774 | 1,149 | 1,618 | 1,680 | 1,007 | 1,811 | 2,215 | 2,351 |
| EPS in Rs | 32.75 | 62.02 | 74.61 | 52.77 | 63.61 | 94.26 | 132.57 | 137.63 | 82.31 | 150.19 | 181.11 | 192.51 |
| Dividend Payout % | 12% | 20% | 20% | 25% | 25% | 27% | 23% | 25% | 61% | 27% | 25% | 28% |
Financials of Alkem Laboratories Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 2,975 | 3,668 | 4,444 | 4,840 | 5,415 | 6,137 | 7,353 | 8,614 | 9,021 | 10,288 | 11,961 | 13,796 |
| Borrowings + | 1,306 | 658 | 659 | 998 | 944 | 1,616 | 1,707 | 2,668 | 1,397 | 1,418 | 1,381 | 2,047 |
| Other Liabilities + | 986 | 1,184 | 1,440 | 1,803 | 1,824 | 2,169 | 2,435 | 2,763 | 3,315 | 3,844 | 4,325 | 5,006 |
| Total Liabilities | 5,291 | 5,534 | 6,568 | 7,664 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 15,575 | 17,691 | 20,873 |
| Fixed Assets + | 1,374 | 1,450 | 1,797 | 2,284 | 2,530 | 2,908 | 2,793 | 2,902 | 2,683 | 2,873 | 2,852 | 4,015 |
| CWIP | 111 | 172 | 299 | 381 | 493 | 363 | 393 | 339 | 323 | 159 | 548 | 138 |
| Investments | 481 | 509 | 553 | 444 | 324 | 261 | 333 | 371 | 622 | 484 | 1,846 | 1,869 |
| Other Assets + | 3,325 | 3,403 | 3,918 | 4,555 | 4,861 | 6,413 | 8,000 | 10,457 | 10,129 | 12,060 | 12,445 | 14,851 |
| Total Assets | 5,291 | 5,534 | 6,568 | 7,664 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 15,575 | 17,691 | 20,873 |
Financials of Alkem Laboratories Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 325 | 726 | 471 | 266 | 780 | 585 | 1,265 | 1,111 | 1,682 | 1,948 | 1,913 | |
| Cash from Investing Activity + | -235 | 205 | -294 | -351 | -318 | -737 | -995 | -1,433 | 120 | -1,011 | -1,288 | |
| Cash from Financing Activity + | -52 | -927 | -138 | 85 | -379 | 79 | -272 | 380 | -1,761 | -1,145 | -811 | |
| Net Cash Flow | 39 | 3 | 40 | 0 | 82 | -73 | -2 | 58 | 42 | -207 | -186 | |
| Free Cash Flow | 190 | 472 | -163 | -411 | 253 | 237 | 1,116 | 783 | 1,453 | 1,761 | 1,278 | |
| CFO/OP | 101% | 107% | 73% | 47% | 92% | 59% | 86% | 73% | 121% | 105% | 96% |
Financials of Alkem Laboratories Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 42 | 46 | 62 | 62 | 72 | 66 | 65 | 67 | 65 | 69 | 74 |
| Inventory Days | 169 | 169 | 198 | 221 | 186 | 198 | 241 | 262 | 194 | 197 | 224 | 239 |
| Days Payable | 101 | 108 | 122 | 147 | 119 | 104 | 112 | 102 | 87 | 129 | 141 | 161 |
| Cash Conversion Cycle | 121 | 103 | 122 | 135 | 129 | 167 | 196 | 225 | 174 | 132 | 152 | 152 |
| Working Capital Days | -52 | 13 | 34 | 40 | 55 | 44 | 48 | 31 | 66 | 135 | 124 | 141 |
| ROCE % | 12% | 23% | 21% | 17% | 16% | 18% | 22% | 18% | 14% | 20% | 20% | 21% |